Submitted:
08 April 2024
Posted:
09 April 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Descriptive Statistics
2.2. Association between Disgust Sensitivity and Steroid Levels in the 1st Trimester
2.3. Association between Disgust Sensitivity and Steroid Levels in the 3rd Trimester
2.4. The Effect of Changes in Steroid Levels during Pregnancy on Changes in Disgust Sensitivity
3. Discussion
- Strengths and Limitations
4. Methods
4.1. Procedure – Data Collection
4.2. Questionnaires
4.3. Laboratory Measurement of Steroid Hormones
4.4. Statistics
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Schaller, M.; Duncan, L.A.; Forges, J.; Haselton, M.; Von Hippel, W. , Evolution and the social mind: Evolutionary psychology and social cognition.. ed.; Psychology press: New York, United States, 2007. [Google Scholar]
- Curtis, V.; Aunger, R.; Rabie, T. , Evidence that disgust evolved to protect from risk of disease. Proceedings. Biological sciences 2004, 271 (Suppl. 4), S131–3. [Google Scholar] [CrossRef] [PubMed]
- Rozin, P.; Fallon, A.E. , A perspective on disgust. Psychological review 1987, 94, 23–41. [Google Scholar] [CrossRef] [PubMed]
- Stevenson, R.J.; Oaten, M.J.; Case, T.I.; Repacholi, B.M.; Wagland, P. , Children's response to adult disgust elicitors: Development and acquisition. Developmental psychology 2010, 46, 165–177. [Google Scholar] [CrossRef] [PubMed]
- Al-Shawaf, L.; Lewis, D.M.G.; Buss, D.M. , Sex Differences in Disgust: Why Are Women More Easily Disgusted Than Men? Emot Rev 2018, 10, 149–160. [Google Scholar] [CrossRef]
- Stevenson, R.J.; Case, T.I.; Oaten, M.J. , Children's response to adult disgust elicitors: Development and acquisition. Evolution and Human Behavior 2010, 30, 363–368. [Google Scholar] [CrossRef]
- Kankova, S.; Takacs, L.; Hlavacova, J.; Calda, P.; Monk, C.; Havlicek, J. , Disgust sensitivity in early pregnancy as a response to high pathogen risk. Frontiers in psychology 2023, 14, 1015927. [Google Scholar] [CrossRef] [PubMed]
- Cepon-Robins, T.J.; Blackwell, A.D.; Gildner, T.E.; Liebert, M.A.; Urlacher, S.S.; Madimenos, F.C.; Eick, G.N.; Snodgrass, J.J.; Sugiyama, L.S. , Pathogen disgust sensitivity protects against infection in a high pathogen environment. Proceedings of the National Academy of Sciences of the United States of America, 2021; 118. [Google Scholar]
- Fessler, D.M.; Navarrete, C.D. , Elevated disgust sensitivity in the first trimester of pregnancy - Evidence supporting prophylaxis the compensatory hypothesis. Evol Hum.Behav 2005, 26, 344–351. [Google Scholar] [CrossRef]
- Dlouha, D.; Roberts, S.C.; Hlavacova, J.; Nouzova, K.; Kankova, S. , Longitudinal changes in disgust sensitivity during pregnancy and the early postpartum period, and the role of recent health problems. Scientific reports 2023, 13, 4752. [Google Scholar] [CrossRef] [PubMed]
- Ille, R.; Schoggl, H.; Kapfhammer, H.P.; Arendasy, M.; Sommer, M.; Schienle, A. , Self-disgust in mental disorders -- symptom-related or disorder-specific? Comprehensive psychiatry 2014, 55, 938–943. [Google Scholar] [CrossRef]
- Olatunji, B.O. , Changes in disgust correspond with changes in symptoms of contamination-based OCD: A prospective examination of specificity. Journal of anxiety disorders 2010, 24, 313–317. [Google Scholar] [CrossRef]
- Fessler, D.M.; Navarrete, C.D. , Domain-specific variation in disgust sensitivity across the menstrual cycle. Evol Hum.Behav 2003, 24, 406–417. [Google Scholar] [CrossRef]
- Miyaura, H.; Iwata, M. , Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. Journal of immunology 2002, 168, 1087–1094. [Google Scholar] [CrossRef]
- Olatunji, B.O.; Cox, R.C.; Li, I. , Disgust regulation between menstrual cycle phases: Differential effects of emotional suppression and reappraisal. Journal of behavior therapy and experimental psychiatry 2020, 68, 101543. [Google Scholar] [CrossRef]
- Dlouha, D.; Ullman, J.; Takacs, L.; Nouzova, K.; Hrbackova, H.; Seda, J.; Kankova, S. , Comparing disgust sensitivity in women in early pregnancy and non-pregnant women in the follicular and luteal phases of the menstrual cycle. Evol Hum Behav 2024. [Google Scholar] [CrossRef]
- Timmers, A.D.; Bossio, J.A.; Chivers, M.L. , Disgust, sexual cues, and the prophylaxis hypothesis. Evol Psychol Sci 2018, 4, 179–190. [Google Scholar] [CrossRef]
- Stern, J.; Shiramizu, V. , Hormones, ovulatory cycle phase and pathogen disgust: A longitudinal investigation of the Compensatory Prophylaxis Hypothesis. Hormones and behavior 2022, 138, 105103. [Google Scholar] [CrossRef]
- Rafiee, Y.; Jones, B.C.; Shiramizu, V. , Is pathogen disgust increased on days of the menstrual cycle when progesterone is high? Evidence from a between-subjects study using estimated progesterone levels. Adapt Hum Behav Physiol 2023, 9, 26–36. [Google Scholar] [CrossRef]
- Zelazniewicz, A.; Borkowska, B.; Nowak, J.; Pawlowski, B. , The progesterone level, leukocyte count and disgust sensitivity across the menstrual cycle. Physiology & behavior 2016, 161, 60–65. [Google Scholar]
- Milkowska, K.; Galbarczyk, A.; Klimek, M.; Zablocka-Slowińska, K.; Jasienska, G. , Pathogen disgust, but not moral disgust, changes across the menstrual cycle. Evol Hum Behav 2021, 42, 402–408. [Google Scholar] [CrossRef]
- Milkowska, K.; Galbarczyk, A.; Jasienska, G. , Disgust sensitivity in relation to menstrual cycle phase in women with and without an infection. American journal of human biology : The official journal of the Human Biology Council 2019, 31, e23233. [Google Scholar] [CrossRef] [PubMed]
- Liu, M.; Zhang, X.; He, Z.; Liang, Y.; Zou, B.; Ma, X.; Gu, S.; Wang, F. , Opposite effects of estradiol and progesterone on woman's disgust processing. Frontiers in psychiatry 2023, 14, 1161488. [Google Scholar] [CrossRef]
- Fleischman, D.S.; Fessler, D.M. , Progesterone's effects on the psychology of disease avoidance: Support for the compensatory behavioral prophylaxis hypothesis. Hormones and behavior 2011, 59, 271–275. [Google Scholar] [CrossRef]
- Conway, C.A.; Jones, B.C.; DeBruine, L.M.; Welling, L.L.; Law Smith, M.J.; Perrett, D.I.; Sharp, M.A.; Al-Dujaili, E.A. , Salience of emotional displays of danger and contagion in faces is enhanced when progesterone levels are raised. Hormones and behavior 2007, 51, 202–206. [Google Scholar] [CrossRef]
- Kamboj, S.K.; Krol, K.M.; Curran, H.V. , A specific association between facial disgust recognition and estradiol levels in naturally cycling women. PLoS ONE 2015, 10, e0122311. [Google Scholar] [CrossRef]
- Kavaliers, M.; Bishnoi, I.R.; Ossenkopp, K.P.; Choleris, E. , Differential effects of progesterone on social recognition and the avoidance of pathogen threat by female mice. Hormones and behavior 2021, 127, 104873. [Google Scholar] [CrossRef]
- Bressan, P.; Kramer, P. , Progesterone does raise disgust. Hormones and behavior 2022, 137, 104937. [Google Scholar] [CrossRef]
- Jones, B.; Hahn, A.; Fisher, C.; Wang, H.; Kandrik, M.; Lee, A.; Tybur, J.; DeBruine, L. , Hormonal correlates of pathogen disgust: Testing the compensatory prophylaxis hypothesis. Evol Hum Behav 2018, 39, 166–169. [Google Scholar] [CrossRef]
- Zelazniewicz, A.; Pawlowski, B. , Disgust in pregnancy and fetus sex--longitudinal study. Physiology & behavior 2015, 139, 177–181. [Google Scholar]
- Racicot, K.; Kwon, J.Y.; Aldo, P.; Silasi, M.; Mor, G. , Understanding the complexity of the immune system during pregnancy. American journal of reproductive immunology 2014, 72, 107–116. [Google Scholar] [CrossRef] [PubMed]
- Hove, C.; Trumble, B.C.; Anderson, A.S.; Stieglitz, J.; Kaplan, H.; Gurven, M.D.; Blackwell, A.D. , Immune function during pregnancy varies between ecologically distinct populations. Evolution, medicine, and public health 2020, 2020, 114–128. [Google Scholar] [CrossRef] [PubMed]
- Abu-Raya, B.; Michalski, C.; Sadarangani, M.; Lavoie, P.M. , Maternal Immunological Adaptation During Normal Pregnancy. Frontiers in immunology 2020, 11, 575197. [Google Scholar] [CrossRef] [PubMed]
- Kankova, S.; Hlavacova, J.; Roberts, K.; Benesova, J.; Havlicek, J.; Calda, P.; Dlouha, D.; Roberts, S.C. , Associations between nausea and vomiting in pregnancy, disgust sensitivity, and first-trimester maternal serum free beta-hCG and PAPP-A. Hormones and behavior 2023, 152, 105360. [Google Scholar] [CrossRef] [PubMed]
- Gerdes, A.B.; Uhl, G.; Alpers, G.W. , Spiders are special: Fear and disgust evoked by pictures of arthropods. Evol Hum Behav 2009, 30, 66–73. [Google Scholar] [CrossRef]
- Cisler, J.M.; Olatunji, B.O.; Lohr, J.M. , Disgust sensitivity and emotion regulation potentiate the effect of disgust propensity on spider fear, blood-injection-injury fear, and contamination fear. Journal of behavior therapy and experimental psychiatry 2009, 40, 219–229. [Google Scholar] [CrossRef] [PubMed]
- Marzillier, S.; Davey, G. , Anxiety and disgust: Evidence for a unidirectional relationship. Cogn Emot 2005, 19, 729–750. [Google Scholar] [CrossRef]
- Silva, M.M.J.; Nogueira, D.A.; Clapis, M.J.; Leite, E. , Anxiety in pregnancy: Prevalence and associated factors. Revista da Escola de Enfermagem da U S P 2017, 51, e03253. [Google Scholar] [CrossRef]
- Fava, G.A.; Grandi, S.; Michelacci, L.; Saviotti, F.; Conti, S.; Bovicelli, L.; Trombini, G.; Orlandi, C. , Hypochondriacal fears and beliefs in pregnancy. Acta psychiatrica Scandinavica 1990, 82, 70–72. [Google Scholar] [CrossRef]
- Odent, M. , Fear of death during labour. Midwifery today with international midwife 2003, 20–22. [Google Scholar] [CrossRef]
- Shlomi Polachek, I.; Huller Harari, L.; Baum, M.; Strous, R.D. , Postpartum anxiety in a cohort of women from the general population: Risk factors and association with depression during last week of pregnancy, postpartum depression and postpartum PTSD. The Israel journal of psychiatry and related sciences 2014, 51, 128–134. [Google Scholar]
- Sterzl, I.; Hill, M.; Starka, L.; Velikova, M.; Kanceva, R.; Jemelkova, J.; Czernekova, L.; Kosztyu, P.; ZadraZil, J.; Matousovic, K.; Vondrak, K.; Raska, M. , Patients with IgA nephropathy have altered levels of immunomodulatory C19 steroids. Glucocorticoid therapy with addition of adrenal androgens may be the choice. Physiological research 2017, 66 (Suppl. 3), S433–S442. [Google Scholar] [CrossRef]
- Honcu, P.; Hill, M.; Bicikova, M.; Jandova, D.; Velikova, M.; Kajzar, J.; Kolatorova, L.; Bestak, J.; Macova, L.; Kancheva, R.; Krejci, M.; Novotny, J.; Starka, L. , Activation of Adrenal Steroidogenesis and an Improvement of Mood Balance in Postmenopausal Females after Spa Treatment Based on Physical Activity. International journal of molecular sciences 2019, 20. [Google Scholar] [CrossRef] [PubMed]
- Olatunji, B.O.; Williams, N.L.; Tolin, D.F.; Abramowitz, J.S.; Sawchuk, C.N.; Lohr, J.M.; Elwood, L.S. , The Disgust Scale: Item analysis, factor structure, and suggestions for refinement. Psychological assessment 2007, 19, 281–297. [Google Scholar] [CrossRef] [PubMed]
- Tybur, J.; Lieberman, D.; Griskevicius, V. , Microbes, Mating, and Morality: Individual Differences in Three Functional Domains of Disgust. Psychiatry investigation 2009, 12, 538–544. [Google Scholar] [CrossRef] [PubMed]
- Erbay, L.G.; Kartalci, S. , Neurosteroid Levels in Patients with Obsessive-Compulsive Disorder. Psychiatry investigation 2015, 12, 538–544. [Google Scholar] [CrossRef] [PubMed]
- Hill, M.; Parizek, A.; Cibula, D.; Kancheva, R.; Jirasek, J.E.; Jirkovska, M.; Velikova, M.; Kubatova, J.; Klimkova, M.; Paskova, A.; Zizka, Z.; Kancheva, L.; Kazihnitkova, H.; Zamrazilova, L.; Starka, L. , Steroid metabolome in fetal and maternal body fluids in human late pregnancy. The Journal of steroid biochemistry and molecular biology 2010, 122, 114–132. [Google Scholar] [CrossRef] [PubMed]
- AbdulHussain, G.; Azizieh, F.; Makhseed, M.; Raghupathy, R. , Effects of Progesterone, Dydrogesterone and Estrogen on the Production of Th1/Th2/Th17 Cytokines by Lymphocytes from Women with Recurrent Spontaneous Miscarriage. Journal of reproductive immunology 2020, 140, 103132. [Google Scholar] [CrossRef] [PubMed]
- Rege, J.; Karashima, S.; Lerario, A.M.; Smith, J.M.; Auchus, R.J.; Kasa-Vubu, J.Z.; Sasano, H.; Nakamura, Y.; White, P.C.; Rainey, W.E. , Age-dependent increases in adrenal cytochrome b5 and serum 5-androstenediol-3-sulfate. J Clin Endocrinol Metab 2016, jc20162864. [Google Scholar] [CrossRef] [PubMed]
- Luu-The, V. , Assessment of steroidogenesis and steroidogenic enzyme functions. The Journal of steroid biochemistry and molecular biology 2013, 137, 176–182. [Google Scholar] [CrossRef]
- Folstad, I.; Karter, A.J. , Parasites, bright males, and the immunocompetence handicap. The Am Nat 1992, 139, 603–622. [Google Scholar] [CrossRef]
- Meulenberg, P.M.; Hofman, J.A. , Maternal testosterone and fetal sex. The Journal of steroid biochemistry and molecular biology 1991, 39, 51–54. [Google Scholar] [CrossRef]
- Bottasso, O.; Bay, M.L.; Besedovsky, H.; del Rey, A. , The immuno-endocrine component in the pathogenesis of tuberculosis. Scand J Immunol 2007, 66, 166–175. [Google Scholar] [CrossRef] [PubMed]
- Du, C.; Khalil, M.W.; Sriram, S. , Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. Journal of immunology 2001, 167, 7094–7101. [Google Scholar] [CrossRef] [PubMed]
- Rontzsch, A.; Thoss, K.; Petrow, P.K.; Henzgen, S.; Brauer, R. , Amelioration of murine antigen-induced arthritis by dehydroepiandrosterone (DHEA). Inflamm Res 2004, 53, 189–198. [Google Scholar] [PubMed]
- Tan, X.D.; Dou, Y.C.; Shi, C.W.; Duan, R.S.; Sun, R.P. , Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 2009, 207, 39–44. [Google Scholar] [CrossRef] [PubMed]
- Choi, I.S.; Cui, Y.; Koh, Y.A.; Lee, H.C.; Cho, Y.B.; Won, Y.H. , Effects of dehydroepiandrosterone on Th2 cytokine production in peripheral blood mononuclear cells from asthmatics. Korean J Intern Med 2008, 23, 176–181. [Google Scholar] [CrossRef] [PubMed]
- Sudo, N.; Yu, X.N.; Kubo, C. , Dehydroepiandrosterone attenuates the spontaneous elevation of serum IgE level in NC/Nga mice. Immunology letters 2001, 79, 177–179. [Google Scholar] [CrossRef] [PubMed]
- Kasperska-Zajac, A.; Brzoza, Z.; Rogala, B. , Dehydroepiandrosterone and dehydroepiandrosterone sulphate in atopic allergy and chronic urticaria. Inflammation 2008, 31, 141–145. [Google Scholar] [CrossRef] [PubMed]
- Sterzl, I.; Hampl, R.; Sterzl, J.; Votruba, J.; Starka, L. , 7Beta-OH-DHEA counteracts dexamethasone induced suppression of primary immune response in murine spleenocytes. The Journal of steroid biochemistry and molecular biology 1999, 71, 133–137. [Google Scholar] [CrossRef] [PubMed]
- Romagnani, S.; Kapsenberg, M.; Radbruch, A.; Adorini, L. , Th1 and Th2 cells. Research in immunology 1998, 149, 871–873. [Google Scholar] [CrossRef]
- Pratschke, S.; von Dossow-Hanfstingl, V.; Dietz, J.; Schneider, C.P.; Tufman, A.; Albertsmeier, M.; Winter, H.; Angele, M.K. , Dehydroepiandrosterone modulates T-cell response after major abdominal surgery. J Surg Res 2014, 189, 117–125. [Google Scholar] [CrossRef]
- Hennebert, O.; Chalbot, S.; Alran, S.; Morfin, R. , Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: Possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes. The Journal of steroid biochemistry and molecular biology 2007, 104, 326–333. [Google Scholar] [CrossRef] [PubMed]
- Le Mee, S.; Hennebert, O.; Ferrec, C.; Wulfert, E.; Morfin, R. , 7beta-Hydroxy-epiandrosterone-mediated regulation of the prostaglandin synthesis pathway in human peripheral blood monocytes. Steroids 2008, 73, 1148–1159. [Google Scholar] [CrossRef] [PubMed]
- Pettersson, H.; Lundqvist, J.; Norlin, M. , Effects of CYP7B1-mediated catalysis on estrogen receptor activation. Biochim Biophys Acta 2010, 1801, 1090–1097. [Google Scholar] [CrossRef] [PubMed]
- Tang, W.; Eggertsen, G.; Chiang, J.Y.; Norlin, M. , Estrogen-mediated regulation of CYP7B1: A possible role for controlling DHEA levels in human tissues. The Journal of steroid biochemistry and molecular biology 2006, 100, 42–51. [Google Scholar] [CrossRef] [PubMed]
- Ahlem, C.N.; Page, T.M.; Auci, D.L.; Kennedy, M.R.; Mangano, K.; Nicoletti, F.; Ge, Y.; Huang, Y.; White, S.K.; Villegas, S.; Conrad, D.; Wang, A.; Reading, C.L.; Frincke, J.M. , Novel components of the human metabolome: The identification, characterization and anti-inflammatory activity of two 5-androstene tetrols. Steroids 2011, 76, 145–155. [Google Scholar] [CrossRef] [PubMed]
- Reading, C.L.; Frincke, J.M.; White, S.K. , Molecular targets for 17alpha-ethynyl-5-androstene-3beta,7beta,17beta-triol, an anti-inflammatory agent derived from the human metabolome. PLoS ONE 2012, 7, e32147. [Google Scholar] [CrossRef] [PubMed]
- Coutinho, A.E.; Chapman, K.E. , The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Molecular and cellular endocrinology 2011, 335, 2–13. [Google Scholar] [CrossRef] [PubMed]
- Cisler, J.M.; Olatunji, B.O.; Lohr, J.M. , Disgust, fear, and the anxiety disorders: A critical review. Clin Psychol Rev 2009, 29, 34–46. [Google Scholar] [CrossRef] [PubMed]
- Olatunji, B.O.; Armstrong, T.; Elwood, L. , Is Disgust Proneness Associated With Anxiety and Related Disorders? A Qualitative Review and Meta-Analysis of Group Comparison and Correlational Studies. Perspectives on psychological science : A journal of the Association for Psychological Science 2017, 12, 613–648. [Google Scholar] [CrossRef] [PubMed]
- Giltay, E.J.; Enter, D.; Zitman, F.G.; Penninx, B.W.; van Pelt, J.; Spinhoven, P.; Roelofs, K. , Salivary testosterone: Associations with depression, anxiety disorders, and antidepressant use in a large cohort study. Journal of psychosomatic research 2012, 72, 205–213. [Google Scholar] [CrossRef]
- Soto-Balbuena, C.; Rodriguez, M.F.; Escudero Gomis, A.I.; Ferrer Barriendos, F.J.; Le, H.N.; Pmb-Huca, G. , Incidence, prevalence and risk factors related to anxiety symptoms during pregnancy. Psicothema 2018, 30, 257–263. [Google Scholar] [PubMed]
- Hill, M.; Hana, V., Jr.; Velikova, M.; Parizek, A.; Kolatorova, L.; Vitku, J.; Skodova, T.; Simkova, M.; Simjak, P.; Kancheva, R.; Koucky, M.; Kokrdova, Z.; Adamcova, K.; Cerny, A.; Hajek, Z.; Duskova, M.; Bulant, J.; Starka, L. , A method for determination of one hundred endogenous steroids in human serum by gas chromatography-tandem mass spectrometry. Physiological research 2019, 68, 179–207. [Google Scholar] [CrossRef] [PubMed]
- Trygg, J.; Wold, S. , Orthogonal projections to latent structures (O-PLS). J. Chemometrics 2002, 16, 119–128. [Google Scholar] [CrossRef]
| Steroids (nM) | Trimester 1 median(quartiles) |
Trimester 3 median(quartiles) |
Trimester 3 – Trimester 1 median(quartiles) |
p-value |
|---|---|---|---|---|
| C21 Δ5 Steroids | ||||
| Pregnenolone | 4.28 (2.86, 6.22) | 4.84 (3.46, 7.32) | 0.563 (-0.812, 2.99) | <0.001 |
| Pregnenolone sulfate | 180 (124, 259) | 212 (161, 295) | 32.6 (-14.1, 84.4) | <0.001 |
| 20α-Dihydropregnenolone | 4.78 (3.55, 6.09) | 3.29 (2.66, 4.32) | -1.23 (-2.44, -0.327) | <0.001 |
| 20α-Dihydropregnenolone sulfate | 954 (639, 1390) | 849 (620, 1100) | -125 (-378, 92.5) | <0.001 |
| 17-Hydroxypregnenolone sulfate | 4.6 (3.07, 7.9) | 2.69 (2.01, 3.98) | -2.04 (-4.86, -0.636) | <0.001 |
| 17-Hydroxypregnenolone | 7.29 (4.63, 12) | 7.39 (5.05, 11.5) | 0.144 (-3.54, 3.08) | 0.704 |
| 16α-Hydroxypregnenolone | 0.462 (0.298, 0.68) | 0.806 (0.589, 1.13) | 0.344 (0.0694, 0.593) | <0.001 |
| C19 Δ5 Steroids | ||||
| Dehydroepiandrosterone (DHEA) | 9.25 (6.01, 12.9) | 4.63 (3.29, 6.87) | -4.12 (-6.63, -1.66) | <0.001 |
| DHEA sulfate | 2900 (1800, 4360) | 1150 (666, 1810) | -1670 (-2560, -910) | <0.001 |
| 7α-Hydroxy-DHEA | 0.909 (0.539, 1.43) | 0.344 (0.228, 0.526) | -0.533 (-0.973, -0.233) | <0.001 |
| 7-oxo-DHEA | 0.503 (0.306, 0.842) | 0.519 (0.41, 0.71) | 0.0141 (-0.307, 0.235) | 0.647 |
| 7β-Hydroxy-DHEA | 0.598 (0.342, 0.885) | 0.285 (0.175, 0.382) | -0.334 (-0.565, -0.124) | <0.001 |
| Androstenediol | 2.72 (1.85, 4.1) | 1.13 (0.741, 2.15) | -1.24 (-2.16, -0.51) | <0.001 |
| Androstenediol sulfate | 322 (194, 512) | 174 (112, 261) | -130 (-307, -25.3) | <0.001 |
| 5-Androstene-3β,7α,17β-triol | 0.459 (0.281, 0.729) | 0.123 (0.084, 0.233) | -0.305 (-0.571, -0.165) | <0.001 |
| 5-Androstene-3β,7β,17β-triol | 0.509 (0.319, 0.873) | 0.231 (0.144, 0.319) | -0.312 (-0.572, -0.134) | <0.001 |
| 5-Androstene-3β,16α,17β-triol | 0.206 (0.131, 0.319) | 0.496 (0.337, 0.788) | 0.266 (0.107, 0.536) | <0.001 |
| 5-Androstene-3β,16α,17β-triol sulfate | 32.6 (18.9, 61.6) | 78.2 (46.9, 139) | 34 (10.5, 78.2) | <0.001 |
| C21 Δ4 Steroids | ||||
| Progesterone | 104 (76.5, 135) | 382 (281, 489) | 277 (183, 390) | <0.001 |
| 20α-Dihydroprogesterone | 22.5 (17.2, 29.2) | 49.2 (36.3, 67.7) | 26.3 (15.6, 43) | <0.001 |
| 17-Hydroxyprogesterone | 11 (8.47, 14.1) | 17.4 (13.8, 21.3) | 5.7 (1.69, 10.9) | <0.001 |
| 16α-Hydroxyprogesterone | 2.14 (1.57, 2.79) | 10.2 (7.62, 14.3) | 8.07 (5.31, 12.2) | <0.001 |
| 17α,20α-Dihydroxy-4-pregnene-3-one | 3.08 (2.18, 4.12) | 4.44 (3.34, 5.85) | 1.25 (0.332, 2.54) | <0.001 |
| C19 Δ4 Steroids | ||||
| Androstenedione | 7.22 (5.44, 9.79) | 6.62 (4.8, 9.26) | -0.966 (-2.54, 0.667) | <0.001 |
| Testosterone | 2.9 (2.1, 3.9) | 2.54 (1.69, 4.17) | -0.245 (-0.805, 0.784) | 0.308 |
| Conjugated testosterone | 1.08 (0.407, 2.39) | 4.2 (2.12, 7.29) | 2.1 (0.335, 5.67) | <0.001 |
| 5α-Dihydrotestosterone | 0.903 (0.596, 1.45) | 0.443 (0.27, 0.682) | -0.446 (-0.761, -0.167) | <0.001 |
| Conjugated 5α-dihydrotestosterone | 1.42 (0.854, 2.09) | 1 (0.677, 1.58) | -0.288 (-1.09, 0.364) | <0.001 |
| Estrogens | ||||
| Estrone | 3.57 (1.99, 6.85) | 17 (10.4, 31.4) | 13.4 (5.26, 29.9) | <0.001 |
| Estrone sulfate | 5.67 (3, 11.7) | 27.3 (16.8, 47.6) | 21.7 (9.41, 38.2) | <0.001 |
| Estradiol | 3.31 (1.55, 5.77) | 31 (18.4, 48.5) | 27 (16.2, 44.4) | <0.001 |
| Estradiol sulfate | 3.98 (2.18, 6.83) | 19.8 (10.3, 35.2) | 15.8 (4.91, 29.6) | <0.001 |
| Estriol | 1.89 (0.726, 4.44) | 74.8 (40.8, 119) | 74.3 (40.9, 116) | <0.001 |
| C21 5α/β-reduced Steroids | ||||
| 5α-Dihydroprogesterone | 10.4 (7.09, 13.7) | 65.1 (42.8, 92.5) | 54.3 (30.7, 80.6) | <0.001 |
| Allopregnanolone | 6.71 (5.05, 9.09) | 31.1 (21.1, 42.7) | 23.8 (14.8, 34) | <0.001 |
| Allopregnanolone sulfate | 128 (82.7, 227) | 1220 (739, 1870) | 1080 (534, 1690) | <0.001 |
| Isopregnanolone | 2.05 (1.38, 2.86) | 7.96 (4.44, 11.9) | 5.28 (2.73, 9.51) | <0.001 |
| Isopregnanolone sulfate | 92.3 (59, 143) | 605 (344, 958) | 477 (263, 837) | <0.001 |
| 5β-Dihydroprogesterone | 0.123 (0.043, 0.235) | 2.02 (1.1, 3.26) | 1.89 (0.978, 3.01) | <0.001 |
| Pregnanolone | 1.91 (1.06, 3.06) | 22.8 (14.5, 29.9) | 20 (13.5, 27.1) | <0.001 |
| Conjugated pregnanolone | 76 (54, 131) | 696 (480, 950) | 549 (361, 806) | <0.001 |
| Epipregnanolone | 0.267 (0.137, 0.538) | 1.36 (0.823, 1.97) | 0.935 (0.596, 1.53) | <0.001 |
| Conjugated epipregnanolone | 23.7 (14.7, 37.3) | 154 (95.4, 255) | 117 (67.8, 207) | <0.001 |
| 17-Hydroxyallopregnanolone | 0.11 (0.04, 0.197) | 0.279 (0.124, 0.511) | 0.149 (0.019, 0.314) | <0.001 |
| 17-Hydroxyallopregnanolone sulfate | 6.6 (3.82, 11) | 11.1 (6.83, 19.5) | 3.48 (0.727, 9.93) | <0.001 |
| 17-Hydroxypregnanolone | 0.195 (0.103, 0.36) | 0.882 (0.595, 1.19) | 0.623 (0.388, 0.899) | <0.001 |
| Conjugated 17α-hydroxypregnanolone | 24.1 (16.8, 39.6) | 46.4 (31, 70.6) | 19.4 (8.95, 35.1) | <0.001 |
| 5α,20α-Tetrahydroprogesterone | 6.04 (4.42, 8.2) | 21.7 (15.1, 31.1) | 15.3 (9.37, 22.2) | <0.001 |
| Conjugated 5α,20α-tetrahydroprogesterone | 5.35 (3.3, 8.59) | 15.5 (10.7, 25.2) | 10.1 (4.74, 18.5) | <0.001 |
| 5α-Pregnane-3α,20α-diol | 7.23 (4.83, 9.68) | 23.1 (16, 32.4) | 14.2 (8.53, 23.9) | <0.001 |
| Conjugated 5α-pregnane-3α,20α-diol | 1650 (1100, 2580) | 6550 (4220, 9420) | 4440 (2660, 7260) | <0.001 |
| 5α-Pregnane-3β,20α-diol | 2.24 (1.57, 3.27) | 6.59 (4.35, 10.5) | 3.65 (2.33, 7.26) | <0.001 |
| Conjugated 5α-pregnane-3β,20α-diol | 3720 (2150, 6210) | 10900 (7600, 17000) | 6550 (3540, 11500) | <0.001 |
| 5β,20α-Tetrahydroprogesterone | 0.096 (0.062, 0.171) | 1.96 (1.4, 2.66) | 1.8 (1.28, 2.47) | <0.001 |
| Conjugated 5β,20α-tetrahydroprogesterone | 2.65 (1.68, 4.06) | 7.48 (5.02, 9.64) | 4.22 (2.05, 6.78) | <0.001 |
| 5β-Pregnane-3α,20α-diol | 0.829 (0.584, 1.21) | 6.61 (5.06, 8.53) | 5.53 (4.19, 7.16) | <0.001 |
| Conjugated 5β-pregnane-3α,20α-diol | 297 (229, 427) | 1070 (794, 1460) | 750 (498, 998) | <0.001 |
| 5β-Pregnane-3β,20α-diol | 0.18 (0.113, 0.313) | 0.593 (0.396, 0.927) | 0.393 (0.209, 0.665) | <0.001 |
| Conjugated 5β-pregnane-3β,20α-diol | 189 (127, 286) | 644 (461, 920) | 430 (253, 624) | <0.001 |
| 5α-Pregnane-3α,17α,20α-triol | 0.276 (0.146, 0.474) | 0.179 (0.104, 0.321) | -0.082 (-0.199, 0.006) | <0.001 |
| Conjugated 5α-pregnane-3α,17α,20α-triol | 28.5 (10.5, 58) | 35.5 (11.8, 87.5) | 3.2 (-5.57, 23.6) | 0.001 |
| 5β-Pregnane-3α,17α,20α-triol | 2.8 (1.88, 3.94) | 4.79 (3.16, 6.17) | 1.52 (0.35, 2.82) | <0.001 |
| Conjugated 5β-pregnane-3α,17α,20α-triol | 116 (82.2, 216) | 162 (117, 269) | 34.8 (-21.4, 102) | <0.001 |
| 5α-Androstane-3,17-dione | 0.521 (0.34, 0.744) | 0.425 (0.297, 0.625) | -0.0559 (-0.197, 0.0546) | <0.001 |
| C19 5α/β-reduced Steroids | ||||
| Androsterone | 0.897 (0.705, 1.21) | 0.568 (0.427, 0.815) | -0.336 (-0.549, -0.12) | <0.001 |
| Androsterone sulfate | 1290 (718, 2100) | 594 (333, 986) | -540 (-1250, -258) | <0.001 |
| Epiandrosterone | 0.333 (0.205, 0.497) | 0.158 (0.102, 0.251) | -0.16 (-0.288, -0.062) | <0.001 |
| Epiandrosterone sulfate | 348 (214, 496) | 129 (76.8, 187) | -199 (-312, -116) | <0.001 |
| Etiocholanolone | 0.265 (0.164, 0.421) | 0.233 (0.148, 0.396) | -0.025 (-0.103, 0.062) | 0.103 |
| Etiocholanolone sulfate | 53.5 (34.2, 84.6) | 36.6 (20, 56.2) | -15.6 (-36.2, -4.48) | <0.001 |
| Epietiocholanolone sulfate | 17 (10.4, 35.5) | 9.45 (6.06, 17.8) | -7.24 (-18.5, -2.09) | <0.001 |
| 5α-Androstane-3α,17β-diol | 0.174 (0.118, 0.245) | 0.079 (0.061, 0.11) | -0.09 (-0.145, -0.05) | <0.001 |
| Conjugated 5α-androstane-3α,17β-diol | 19.7 (14.2, 28.7) | 13.2 (8.46, 18) | -7.12 (-14.7, -1.3) | <0.001 |
| 5α-Androstane-3β,17β-diol | 0.064 (0.024, 0.141) | 0.032 (0.01, 0.075 | -0.022 (-0.081, -0.002) | <0.001 |
| Conjugated 5α-androstane-3β,17β-diol | 26.6 (16.1, 56.5) | 12.5 (7.12, 23.6) | -14.8 (-35.1, -4.69) | <0.001 |
| 5β-Androstane-3α,17β-diol | 0.011 (0.006, 0.018) | 0.007 (0.003, 0.013) | -0.004 (-0.009, 0.002) | <0.001 |
| Conjugated 5β-androstane-3α,17β-diol | 3.98 (2.5, 6.59) | 2.85 (1.78, 4.9) | -0.916 (-2.09, 0.272) | <0.001 |
| Corticoids and 11β-hydroxy-androstanes | ||||
| Cortisol | 389 (308, 473) | 632 (537, 824) | 231 (148, 386) | <0.001 |
| Cortisone | 106 (77.1, 148) | 170 (128, 252) | 52.8 (22.8, 111) | <0.001 |
| Corticosterone | 12.5 (7.38, 18.6) | 19.5 (14.6, 27.2) | 6.96 (-0.918, 14.7) | <0.001 |
| 11-Deoxycortisol | 0.74 (0.168, 1.87) | 3.49 (1.06, 7.02) | 2.57 (0.423, 5.22) | <0.001 |
| 21-Deoxycortisol | 0.081 (0.029, 0.243) | 0.117 (0.0656, 0.259) | 0.029 (-0.025, 0.098) | <0.001 |
| 3α,5α-Tetrahydrocorticosterone | 0.039 (0.0173, 0.087) | 0.028 (0.010, 0.056) | -0.009 (-0.043, 0.003) | <0.001 |
| 3α,5β-Tetrahydrocorticosterone | 0.124 (0.0409, 0.328) | 0.06 (0.022, 0.127) | -0.052 (-0.228, 0.0112) | <0.001 |
| 11β-Hydroxyandrostenedione | 48.3 (29.9, 74.9) | 60 (39.5, 102) | 8.58 (-1.77, 30) | <0.001 |
| 11β-Hydroxyandrosterone | 1.2 (0.702, 2.14) | 0.316 (0.188, 0.528) | -0.897 (-1.73, -0.432) | <0.001 |
| 11β-Hydroxyandrosterone sulfate | 12.2 (8.5, 18.3) | 7.45 (4.59, 11.6) | -4.56 (-9.27, -0.811) | <0.001 |
| 11β-Hydroxyepiandrosterone | 0.048 (0.023, 0.101) | 0.012 (0.005, 0.025) | -0.031 (-0.074, -0.009) | <0.001 |
| 11β-Hydroxyepiandrosterone sulfate | 0.783 (0.413, 1.25) | 1.81 (0.938, 3.18) | 0.974 (0.203, 1.94) | <0.001 |
| 11β-Hydroxyetiocholanolone | 0.927 (0.576, 1.39) | 0.422 (0.241, 0.673) | -0.44 (-0.799, -0.213) | <0.001 |
| 11β-Hydroxyetiocholanolone sulfate | 3.01 (1.82, 4.85) | 1.77 (1.05, 2.93) | -1.06 (-2.17, -0.174) | <0.001 |
| Questionnaire | n | Mean | Median (quartiles) |
SD | Min. | Max. | Cronbach’s alpha |
|---|---|---|---|---|---|---|---|
| Overall DS-R T1 | 169 | 56.2 | 55 (45, 66) | 14.3 | 21 | 93 | 0.843 |
| Overall DS-R T3 | 176 | 55.1 | 56 (44.8, 66) | 15.3 | 15 | 91 | 0.874 |
| Core T1 | 169 | 29.4 | 30 (25, 35) | 6.96 | 11 | 48 | 0.676 |
| Core T3 | 176 | 28.4 | 28 (23, 34) | 7.56 | 8 | 47 | 0.763 |
| Contamination T1 | 169 | 8.53 | 8 (6, 11) | 3.62 | 2 | 19 | 0.562 |
| Contamination T3 | 176 | 8.53 | 9 (6,11) | 3.70 | 0 | 19 | 0.622 |
| Animal reminder T1 | 169 | 18.3 | 18 (14, 23) | 6.37 | 3 | 32 | 0.760 |
| Animal reminder T3 | 176 | 18.2 | 19 (13, 23) | 6.66 | 0 | 32 | 0.792 |
| Pathogen TDDS T1 | 174 | 23.3 | 24 (17, 28) | 7.35 | 4 | 40 | 0.734 |
| Pathogen TDDS T3 | 176 | 23.4 | 23 (18, 29) | 7.70 | 7 | 41 | 0.798 |
| OPLS (predictive component) |
Multiple regression |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Variable importance | t-statistics | Component loading | t-statistics | Ra | Regression coefficient | t-statistics | ||||
| DS-R, Overall score | |||||||||||
| Androstenediol | 0.988 | 2.91 | * | 0.289 | 8.96 | 0.559 | ** | 0.045 | 3.32 | ** | |
| Estrone | 0.939 | 3.24 | ** | -0.062 | -2.43 | -0.114 | * | -0.042 | -2.15 | * | |
| 17-Hydroxypregnanolone | 1.245 | 2.88 | * | 0.225 | 3.18 | 0.434 | ** | 0.056 | 2.72 | * | |
| 5β-Pregnane-3α,17α,20α-triol | 0.789 | 2.04 | * | 0.228 | 4.58 | 0.441 | ** | 0.036 | 2.60 | * | |
| 5α-Androstane-3,17-dione | 1.025 | 4.26 | ** | 0.361 | 11.28 | 0.697 | ** | 0.046 | 3.35 | ** | |
| Androsterone | 1.096 | 3.30 | ** | 0.388 | 9.55 | 0.750 | ** | 0.049 | 3.13 | ** | |
| Androsterone sulfate | 0.981 | 3.68 | ** | 0.310 | 11.08 | 0.595 | ** | 0.044 | 2.21 | * | |
| Epiandrosterone | 1.010 | 2.81 | * | 0.389 | 7.71 | 0.752 | ** | 0.046 | 1.95 | * | |
| Epiandrosterone sulfate | 1.092 | 5.81 | ** | 0.332 | 7.09 | 0.640 | ** | 0.049 | 3.21 | ** | |
| 5α-Androstane-3α,17β-diol | 0.822 | 2.76 | * | 0.354 | 8.29 | 0.686 | ** | 0.037 | 4.73 | ** | |
| 5α-Androstane-3β,17β-diol | 1.007 | 2.34 | * | 0.308 | 10.12 | 0.595 | ** | 0.045 | 2.08 | * | |
| 5β-Androstane-3α,17β-diol | 1.082 | 2.35 | * | 0.194 | 4.04 | 0.369 | ** | 0.049 | 2.09 | * | |
| 3α,5β-Tetrahydrocorticosterone | 0.825 | 2.57 | * | 0.165 | 3.05 | 0.320 | ** | 0.037 | 1.66 | ||
| DS-R, Overall score, trimester 1 | 1.000 | 2.91 | 0.313 | * | |||||||
| Explained variability | 9.8% (6.8% after cross-validation) | ||||||||||
| DS-R, Core disgust | |||||||||||
| Androstenediol | 0.998 | 2.34 | * | 0.305 | 9.63 | 0.610 | ** | 0.051 | 2.14 | * | |
| Testosterone | 1.199 | 4.01 | ** | 0.336 | 6.80 | 0.672 | ** | 0.061 | 3.96 | ** | |
| 5α-Dihydrotestosterone | 0.974 | 3.16 | ** | 0.389 | 16.63 | 0.780 | ** | 0.050 | 2.78 | * | |
| Estradiol sulfate | 0.709 | 2.36 | * | -0.017 | -0.41 | -0.028 | -0.036 | -2.56 | * | ||
| Conjugated pregnanolone | 0.598 | 1.94 | * | -0.166 | -3.24 | -0.327 | ** | -0.031 | -2.06 | * | |
| 5α-Androstane-3,17-dione | 1.110 | 3.52 | ** | 0.359 | 5.49 | 0.719 | ** | 0.057 | 3.46 | ** | |
| Androsterone | 0.923 | 8.32 | ** | 0.394 | 13.88 | 0.788 | ** | 0.047 | 7.34 | ** | |
| Androsterone sulfate | 0.988 | 3.28 | ** | 0.315 | 5.40 | 0.632 | ** | 0.051 | 3.18 | ** | |
| Epiandrosterone sulfate | 0.944 | 3.92 | ** | 0.334 | 8.53 | 0.670 | ** | 0.048 | 3.79 | ** | |
| 5α-Androstane-3α,17β-diol | 1.139 | 4.40 | ** | 0.409 | 16.91 | 0.820 | ** | 0.058 | 4.31 | ** | |
| Conjugated 5α-androstane-3β,17β-diol | 1.230 | 6.41 | ** | 0.216 | 6.00 | 0.423 | ** | 0.063 | 6.28 | ** | |
| DS-R, Core disgust, trimester 1 | 1.000 | 7.40 | 0.338 | ** | |||||||
| Explained variability | 11.4% (9.7% after cross-validation) | ||||||||||
| DS-R, Contamination disgust | |||||||||||
| DHEA sulfate | 0.474 | 1.60 | 0.383 | 8.32 | 0.651 | ** | 0.026 | 1.33 | |||
| Conjugated testosterone | 0.860 | 2.73 | * | -0.083 | -1.21 | -0.138 | -0.047 | -2.13 | * | ||
| Estrone | 0.844 | 6.58 | ** | 0.216 | 5.37 | 0.363 | ** | 0.046 | 3.91 | ** | |
| 17-Hydroxypregnanolone | 0.896 | 2.29 | * | 0.090 | 0.84 | 0.151 | 0.049 | 2.89 | * | ||
| Androsterone sulfate | 1.273 | 2.75 | * | 0.468 | 8.75 | 0.796 | ** | 0.069 | 2.42 | * | |
| Epiandrosterone sulfate | 1.280 | 3.40 | ** | 0.496 | 9.37 | 0.842 | ** | 0.069 | 2.71 | * | |
| Etiocholanolone sulfate | 0.826 | 2.34 | * | 0.386 | 12.44 | 0.659 | ** | 0.045 | 2.09 | * | |
| Epitetiocholanolone sulfate | 1.260 | 2.95 | * | 0.446 | 11.03 | 0.743 | ** | 0.068 | 2.73 | * | |
| Conjugated 5α-androstane-3β,17β-diol | 0.996 | 2.39 | * | 0.375 | 5.34 | 0.641 | ** | 0.054 | 1.81 | ||
| DS-R, Contamination disgust, trimester 1 | 1.000 | 2.14 | 0.276 | * | |||||||
| Explained variability | 7.6% (4.8% after cross-validation) | ||||||||||
| DS-R, Animal reminder disgust | |||||||||||
| Testoterone | 0.752 | 2.24 | * | 0.328 | 2.90 | 0.505 | * | 0.061 | 1.89 | ||
| Estrone | 1.072 | 4.66 | ** | 0.450 | 10.64 | 0.723 | ** | 0.087 | 5.98 | ** | |
| Estradiol | 1.243 | 6.54 | ** | 0.444 | 11.46 | 0.676 | ** | 0.100 | 4.63 | ** | |
| 5β,20α-Tetrahydroprogesterone | 0.833 | 2.02 | * | 0.376 | 3.65 | 0.576 | ** | 0.067 | 2.14 | * | |
| Conjugated 5β-androstane-3α,17β-diol | 0.940 | 3.08 | ** | 0.393 | 6.55 | 0.605 | ** | 0.076 | 2.89 | * | |
| 5α-Androstane-3,17-dione | 1.078 | 3.89 | ** | 0.449 | 8.42 | 0.690 | ** | 0.087 | 3.03 | ** | |
| DS-R, Animal reminder disgust, trimester 1 | 1.000 | 2.57 | 0.303 | * | |||||||
| Explained variability | 9.2% (7.4% after cross-validation) | ||||||||||
| OPLS (predictive component) |
Multiple regression |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Variable importance | t-statistics |
Component loading | t-statistics | Ra |
Regression coefficient | t-statistics | ||||
| Testosterone | 0.521 | 1.94 | * | 0.137 | 1.27 | 0.195 | 0.056 | 1.71 | |||
| 5α-Dihydrotestosterone | 0.896 | 3.30 | ** | 0.331 | 6.40 | 0.468 | ** | 0.097 | 2.45 | * | |
| Estradiol | 0.766 | 2.72 | * | 0.168 | 2.53 | 0.231 | * | 0.083 | 2.66 | * | |
| 5β,20α-Tetrahydroprogesterone | 1.127 | 3.50 | ** | -0.326 | -2.76 | -0.462 | * | -0.122 | -3.41 | ** | |
| 5β-Pregnane-3α,17α,20α-triol | 0.792 | 2.11 | * | 0.494 | 9.74 | 0.698 | ** | 0.086 | 1.98 | * | |
| Conjugated 5α-androstane-3β,17β-diol | 1.565 | 5.93 | ** | 0.567 | 8.51 | 0.800 | ** | 0.169 | 6.74 | ** | |
| 5α-Androstane-3,17-dione | 0.996 | 6.58 | ** | 0.504 | 10.66 | 0.712 | ** | 0.108 | 4.69 | ** | |
| TDDS, pathogen disgust in trimester 1 | 1.000 | 4.38 | 0.407 | ** | |||||||
| Explained variability | 16.6% (13.5% after cross-validation) | ||||||||||
| OPLS (predictive component) |
Multiple regression |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Variable importance | t-statistics | Component loading | t-statistics | Ra | Regression coefficient | t-statistics | ||||
| DS-R, Overall score | |||||||||||
| 7α-Hydroxy-DHEA | 0.757 | 1.96 | * | 0.390 | 8.96 | 0.626 | ** | 0.091 | 2.18 | * | |
| Androstenediol | 0.856 | 3.01 | ** | 0.356 | 6.13 | 0.572 | ** | 0.152 | 2.69 | * | |
| 5β-Androstane-3α,17β-diol | 1.213 | 8.34 | ** | 0.401 | 12.35 | 0.641 | ** | 0.164 | 2.37 | * | |
| Cortisol | 0.961 | 4.38 | ** | 0.364 | 7.18 | 0.584 | ** | 0.137 | 3.89 | ** | |
| DS-R, Overall score, trimester 3 | 1.000 | 4.30 | 0.415 | ** | |||||||
| Explained variability | 11.7% (8.8% after cross-validation) | ||||||||||
| DS-R, Core disgust | |||||||||||
| Pregnenolone | 0.785 | 2.65 | * | 0.202 | 4.88 | 0.419 | ** | 0.041 | 1.85 | ||
| 17-Hydroxypregnenolone | 1.361 | 4.82 | ** | 0.377 | 10.59 | 0.782 | ** | 0.071 | 5.51 | ** | |
| Dehydroepiandrosterone | 0.924 | 3.14 | ** | 0.386 | 9.49 | 0.801 | ** | 0.048 | 2.66 | * | |
| 7α-Hydroxy-DHEA | 1.153 | 5.17 | ** | 0.407 | 16.53 | 0.844 | ** | 0.060 | 3.29 | ** | |
| 7β-Hydroxy-DHEA | 1.030 | 4.15 | ** | 0.374 | 10.36 | 0.775 | ** | 0.054 | 2.56 | * | |
| Androstenediol | 1.125 | 5.00 | ** | 0.275 | 8.36 | 0.569 | ** | 0.059 | 3.68 | ** | |
| 5-Androstene-3 β,7α,17β-triol | 0.984 | 2.89 | * | 0.336 | 11.14 | 0.696 | ** | 0.051 | 1.97 | * | |
| 5α-Dihydrotestosterone | 0.566 | 2.21 | * | 0.210 | 6.00 | 0.434 | ** | 0.029 | 2.20 | * | |
| Epiandrosterone | 1.053 | 3.40 | ** | 0.345 | 6.85 | 0.716 | ** | 0.055 | 6.77 | ** | |
| 5α-Androstane-3β,17β-diol | 0.792 | 2.45 | * | 0.200 | 5.18 | 0.415 | ** | 0.041 | 1.76 | ||
| DS-R, Core disgust, trimester 3 | 1.000 | 3.01 | 0.342 | ** | |||||||
| Explained variability | 11.7% (8.8% after cross-validation) | ||||||||||
| DS-R, Contamination disgust | |||||||||||
| Pregnenolone | 0.690 | 3.19 | ** | 0.158 | 2.33 | 0.222 | * | 0.105 | 2.24 | * | |
| Testosterone | 1.048 | 4.14 | ** | -0.376 | -5.44 | -0.546 | ** | -0.151 | -4.06 | ** | |
| Estradiol sulfate | 0.950 | 2.59 | * | -0.269 | -2.70 | -0.393 | * | -0.158 | -2.06 | * | |
| Estriol sulfate | 0.636 | 2.53 | * | -0.167 | -1.85 | -0.255 | -0.134 | -2.69 | * | ||
| Conjugated pregnanolone | 1.032 | 5.42 | ** | 0.318 | 6.55 | 0.445 | ** | 0.035 | 0.90 | ||
| Conjugated epipregnanolone | 1.026 | 2.79 | * | 0.310 | 2.92 | 0.431 | * | 0.052 | 1.08 | ||
| Conjugated 5α,20α-tetrahydroprogesterone | 1.140 | 5.96 | ** | 0.301 | 4.73 | 0.410 | ** | 0.095 | 3.07 | ** | |
| Conjugated 5α-pregnane-3α,20α-diol | 1.131 | 3.01 | ** | 0.270 | 3.00 | 0.368 | ** | 0.103 | 1.32 | ||
| Conjugated 5β,20α-tetrahydroprogesterone | 0.978 | 2.60 | * | 0.265 | 2.62 | 0.362 | * | 0.080 | 0.95 | ||
| Conjugated 5β-pregnane-3β,20α-diol | 0.877 | 4.29 | ** | 0.282 | 3.94 | 0.386 | ** | 0.025 | 0.73 | ||
| Maternal age | 1.357 | 3.74 | ** | 0.390 | 3.65 | 0.569 | ** | 0.237 | 3.60 | ** | |
| Multipara (1:yes/0:no) | 0.925 | 3.14 | ** | 0.292 | 2.89 | 0.428 | * | 0.185 | 5.37 | ** | |
| DS-R, Contamination disgust, trimester 3 | 1.000 | 13.56 | 0.570 | ** | |||||||
| Explained variability | 32.5% (23.1% after cross-validation) | ||||||||||
| DS-R, Animal reminder disgust | |||||||||||
| Epiandrosterone | 1.080 | 4.83 | ** | 0.532 | 7.50 | 0.676 | ** | 0.135 | 4.59 | ** | |
| 5α-Androstane-3β,17β-diol | 0.894 | 2.93 | * | 0.505 | 6.19 | 0.641 | ** | 0.112 | 2.34 | * | |
| 5β-Androstane-3α,17β-diol | 0.951 | 4.60 | ** | 0.477 | 7.10 | 0.605 | ** | 0.119 | 3.54 | ** | |
| Conjugated 5β-androstane-3α,17β-diol | 1.063 | 2.98 | * | 0.489 | 3.08 | 0.613 | ** | 0.133 | 2.50 | * | |
| DS-R, Animal reminder disgust, trimester 3 | 1.000 | 2.09 | 0.317 | * | |||||||
| Explained variability | 10% (7.8% after cross-validation) | ||||||||||
| OPLS (predictive component) |
Multiple regression |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Variable importance | t-statistics | Component loading | t-statistics | Ra | Regression coefficient | t-statistics | ||||
| DHEA | 0.737 | 3.04 | ** | 0.368 | 5.37 | 0.667 | ** | 0.056 | 2.72 | * | |
| DHEA sulfate | 0.907 | 3.42 | ** | 0.431 | 14.40 | 0.783 | ** | 0.068 | 3.21 | ** | |
| Androstenediol | 0.533 | 1.93 | * | 0.283 | 4.15 | 0.513 | ** | 0.040 | 2.46 | * | |
| Androsterone sulfate | 1.116 | 6.79 | ** | 0.428 | 12.16 | 0.778 | ** | 0.084 | 5.63 | ** | |
| Epiandrosterone | 1.383 | 5.35 | ** | 0.426 | 10.60 | 0.773 | ** | 0.104 | 5.53 | ** | |
| Epiandrosterone sulfate | 1.129 | 5.90 | ** | 0.465 | 17.83 | 0.845 | ** | 0.085 | 3.84 | ** | |
| 5β-Androstane-3α,17β-diol | 0.957 | 2.90 | * | 0.250 | 2.87 | 0.453 | * | 0.072 | 2.17 | * | |
| TDDS, Pathogen disgust, trimester 3 | 1.000 | 6.00 | 0.361 | ** | |||||||
| Explained variability | 13% (11.1% after cross-validation) | ||||||||||
| OPLS (predictive component) |
Multiple regression |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Variable importance | t-statistics | Component loading | t-statistics | Ra | Regression coefficient | t-statistics | ||||
| ΔDS-R, Overall score | |||||||||||
| Pregnenolone sulfate | 0.771 | 2.97 | * | -0.180 | -8.45 | -0.527 | ** | -0.021 | -3.14 | ** | |
| 17-Hydroxypregnenolone sulfate | 0.617 | 2.77 | * | -0.162 | -5.63 | -0.470 | ** | -0.017 | -2.69 | * | |
| 16α-Hydroxypregnenolone | 0.764 | 3.25 | ** | -0.194 | -6.32 | -0.569 | ** | -0.021 | -3.56 | ** | |
| DHEA sulfate | 1.080 | 2.44 | * | -0.207 | -5.54 | -0.605 | ** | -0.030 | -2.85 | * | |
| 7α-Hydroxy-DHEA | 0.793 | 2.73 | * | -0.237 | -5.40 | -0.693 | ** | -0.022 | -3.93 | ** | |
| 7α-oxo-DHEA | 0.642 | 2.71 | * | -0.152 | -10.42 | -0.444 | ** | -0.018 | -2.29 | * | |
| Androstenediol | 0.641 | 3.62 | ** | -0.185 | -6.52 | -0.541 | ** | -0.018 | -3.16 | ** | |
| Androstenediol sulfate | 0.852 | 4.59 | ** | -0.122 | -3.62 | -0.355 | ** | -0.023 | -4.11 | ** | |
| 20α-Dihydroprogesterone | 0.664 | 1.98 | * | -0.092 | -2.22 | -0.268 | * | -0.018 | -1.53 | ||
| 17-Hydroxyprogesterone | 0.955 | 4.46 | ** | -0.146 | -4.67 | -0.428 | ** | -0.026 | -3.39 | ** | |
| 16α-Hydroxyprogesterone | 1.179 | 6.49 | ** | -0.144 | -4.17 | -0.420 | ** | -0.032 | -3.91 | ** | |
| 17,20α-Dihydroxy-4-pregnen-3-one | 0.919 | 3.25 | ** | -0.179 | -6.10 | -0.527 | ** | -0.025 | -2.61 | * | |
| Androstenedione | 1.266 | 6.07 | ** | -0.227 | -9.73 | -0.663 | ** | -0.035 | -3.75 | ** | |
| Testosterone | 1.416 | 9.51 | ** | -0.232 | -8.69 | -0.680 | ** | -0.039 | -4.74 | ** | |
| 5α-Dihydrotestosterone | 1.164 | 5.27 | ** | -0.244 | -17.51 | -0.712 | ** | -0.032 | -4.52 | ** | |
| Estrone | 0.718 | 3.21 | ** | -0.094 | -4.67 | -0.265 | ** | -0.020 | -4.78 | ** | |
| Estradiol | 0.779 | 2.92 | * | -0.105 | -4.24 | -0.304 | ** | -0.021 | -2.62 | * | |
| 17α-Hydroxyallopregnanolone | 1.242 | 3.34 | ** | -0.167 | -4.75 | -0.490 | ** | -0.034 | -2.33 | * | |
| 17α-Hydroxypregnanolone | 1.305 | 3.71 | ** | -0.125 | -2.41 | -0.366 | * | -0.036 | -2.35 | * | |
| 5β-Pregnane-3α,17,20α-triol | 0.970 | 3.31 | ** | -0.140 | -4.81 | -0.412 | ** | -0.027 | -2.44 | * | |
| 5α-Androstane-3,17-dione | 1.437 | 4.69 | ** | -0.233 | -6.53 | -0.682 | ** | -0.039 | -3.48 | ** | |
| Androsterone | 1.552 | 12.86 | ** | -0.275 | -15.44 | -0.804 | ** | -0.042 | -4.75 | ** | |
| Androsterone sulfate | 0.799 | 2.57 | * | -0.134 | -4.14 | -0.391 | ** | -0.022 | -2.89 | * | |
| Epiandrosterone | 1.295 | 6.09 | ** | -0.260 | -9.38 | -0.761 | ** | -0.035 | -4.87 | ** | |
| Epiandrosterone sulfate | 0.808 | 1.93 | * | -0.151 | -5.84 | -0.441 | ** | -0.022 | -2.19 | * | |
| 5α-Androstane-3α,17β-diol | 1.619 | 12.04 | ** | -0.260 | -14.96 | -0.762 | ** | -0.044 | -6.40 | ** | |
| 5α-Androstane-3β,17β-diol | 1.184 | 5.87 | ** | -0.192 | -10.04 | -0.561 | ** | -0.032 | -7.80 | ** | |
| Maternal age | 0.692 | 2.67 | * | 0.125 | 3.89 | 0.364 | ** | 0.019 | 2.08 | * | |
| Male sex of the fetus | 0.790 | 2.16 | * | -0.035 | -1.26 | -0.103 | -0.022 | -2.45 | * | ||
| DSR_Overall score | 0.851 | 3.18 | ** | -0.066 | -2.62 | -0.194 | * | -0.023 | -2.64 | * | |
| Pregnancy length | 0.564 | 2.04 | * | 0.051 | 2.65 | 0.148 | * | 0.015 | 2.27 | * | |
| ΔDHEA sulfate | 1.128 | 2.11 | * | 0.194 | 5.72 | 0.566 | ** | 0.031 | 2.27 | * | |
| ΔAndrostenediol | 0.857 | 2.49 | * | 0.156 | 4.55 | 0.458 | ** | 0.023 | 2.07 | * | |
| Δ5α-Dihydrotestosterone | 0.980 | 4.69 | ** | 0.149 | 5.41 | 0.437 | ** | 0.027 | 5.27 | ** | |
| ΔAndrosterone | 0.754 | 3.00 | * | 0.142 | 8.92 | 0.418 | ** | 0.021 | 2.54 | * | |
| Δ5α-Androstane-3β,17β-diol | 0.848 | 2.06 | * | 0.104 | 5.15 | 0.303 | ** | 0.023 | 2.39 | * | |
| ΔAndrostenediol sulfate | 0.608 | 2.34 | * | 0.010 | 0.31 | 0.029 | 0.017 | 2.31 | * | ||
| ΔDS-R, Overall score | 1.000 | 11.93 | 0.486 | ** | |||||||
| Explained variability | 23.7% (19.3% after cross-validation) | ||||||||||
| ΔDS-R, Core disgust | |||||||||||
| 17-Hydroxyprogesterone | 0.914 | 2.49 | * | -0.257 | -2.99 | -0.519 | * | -0.044 | -1.82 | ||
| 16α-Hydroxyprogesterone | 0.771 | 3.95 | ** | -0.203 | -2.47 | -0.410 | * | -0.037 | -2.45 | * | |
| Androstenedione | 0.929 | 2.58 | * | -0.361 | -7.89 | -0.729 | ** | -0.045 | -2.12 | * | |
| Testosterone | 0.886 | 11.65 | ** | -0.349 | -14.24 | -0.702 | ** | -0.043 | -4.23 | ** | |
| 17-Hydroxypregnanolone | 1.238 | 2.91 | * | -0.220 | -2.24 | -0.446 | * | -0.060 | -2.07 | * | |
| 5α-Androstane-3,17-dione | 0.793 | 4.33 | ** | -0.359 | -16.89 | -0.724 | ** | -0.038 | -2.82 | * | |
| Androsterone | 0.862 | 4.60 | ** | -0.373 | -7.41 | -0.752 | ** | -0.042 | -3.36 | ** | |
| Androsterone sulfate | 1.379 | 5.09 | ** | -0.288 | -3.92 | -0.573 | ** | -0.067 | -7.75 | ** | |
| Epiandrosterone sulfate | 1.194 | 4.75 | ** | -0.295 | -3.48 | -0.587 | ** | -0.058 | -10.59 | ** | |
| Epietiocholanolone sulfate | 0.769 | 2.34 | * | -0.227 | -2.75 | -0.450 | * | -0.037 | -2.89 | * | |
| 5α-Androstane-3α,17β-diol | 1.068 | 2.74 | * | -0.342 | -6.91 | -0.689 | ** | -0.052 | -2.78 | * | |
| 5α-Androstane-3β,17β-diol | 0.839 | 4.42 | ** | -0.273 | -4.22 | -0.550 | ** | -0.041 | -6.07 | ** | |
| DS-R, Overall score | 1.121 | 3.30 | ** | -0.154 | -2.42 | -0.312 | * | -0.054 | -3.09 | ** | |
| ΔDS-R, Core disgust | 1.000 | 2.80 | 0.352 | * | |||||||
| Explained variability | 12.4% (9.9% after cross-validation) | ||||||||||
| ΔDS-R, Contamination disgust | |||||||||||
| Pregnenolone sulfate | 0.695 | 2.53 | * | -0.190 | -10.55 | -0.427 | ** | -0.031 | -2.05 | * | |
| 20α-Dihydropregnenolone | 0.868 | 4.04 | ** | -0.145 | -5.26 | -0.325 | ** | -0.038 | -4.67 | ** | |
| DHEA sulfate | 0.730 | 2.68 | * | -0.205 | -5.05 | -0.460 | ** | -0.032 | -3.03 | ** | |
| Androstenediol | 0.872 | 4.48 | ** | -0.207 | -8.62 | -0.468 | ** | -0.039 | -5.64 | ** | |
| Androstenediol sulfate | 0.912 | 3.64 | ** | -0.141 | -3.66 | -0.316 | ** | -0.040 | -2.66 | * | |
| Androstenedione | 1.171 | 2.79 | * | -0.280 | -7.71 | -0.633 | ** | -0.052 | -3.31 | ** | |
| Testosterone | 1.041 | 2.11 | * | -0.278 | -4.95 | -0.628 | ** | -0.046 | -2.26 | * | |
| Estrone | 0.935 | 2.73 | * | -0.186 | -5.90 | -0.399 | ** | -0.041 | -2.63 | * | |
| Allopregnanolone | 0.942 | 4.42 | ** | -0.172 | -4.80 | -0.389 | ** | -0.042 | -4.26 | ** | |
| Allopregnanolone sulfate | 0.709 | 2.18 | * | -0.073 | -1.89 | -0.164 | -0.031 | -1.85 | |||
| Isopregnanolone sulfate | 0.785 | 1.90 | * | -0.104 | -2.76 | -0.233 | * | -0.035 | -1.59 | ||
| 17α-Hydroxypregnanolone | 1.275 | 2.97 | * | -0.199 | -5.27 | -0.448 | ** | -0.056 | -3.48 | ** | |
| 5α,20α-Tetrahydroprogesterone | 0.914 | 4.62 | ** | -0.164 | -3.81 | -0.372 | ** | -0.040 | -3.60 | ** | |
| 5α-Pregnane-3α,20α-diol | 0.632 | 4.27 | ** | -0.150 | -4.82 | -0.338 | ** | -0.028 | -5.52 | ** | |
| 5β-Pregnane-3α,20α-diol | 0.733 | 2.60 | * | -0.150 | -4.56 | -0.340 | ** | -0.032 | -2.89 | * | |
| 5β-Pregnane-3β,20α-diol | 0.900 | 4.13 | ** | -0.130 | -3.59 | -0.279 | ** | -0.040 | -4.20 | ** | |
| 5β-Pregnane-3α,17α,20α-triol | 0.967 | 2.73 | * | -0.203 | -5.01 | -0.457 | ** | -0.043 | -2.90 | * | |
| 5α-Androstane-3,17-dione | 1.274 | 5.03 | ** | -0.318 | -13.20 | -0.720 | ** | -0.056 | -3.40 | ** | |
| Androsterone | 1.222 | 5.01 | ** | -0.319 | -9.19 | -0.720 | ** | -0.054 | -5.36 | ** | |
| Androsterone sulfate | 1.384 | 6.74 | ** | -0.246 | -6.37 | -0.553 | ** | -0.061 | -5.98 | ** | |
| Epiandrosterone | 0.761 | 3.80 | ** | -0.269 | -17.69 | -0.609 | ** | -0.034 | -2.80 | * | |
| Epiandrosterone sulfate | 1.181 | 4.83 | ** | -0.246 | -8.24 | -0.551 | ** | -0.052 | -3.88 | ** | |
| Etiocholanolone | 0.818 | 2.29 | * | -0.131 | -2.69 | -0.296 | * | -0.036 | -2.56 | * | |
| Conjugated 5α-androstane-3α,17β-diol | 0.870 | 3.59 | ** | -0.151 | -3.41 | -0.336 | ** | -0.039 | -3.15 | ** | |
| Conjugated 5α-androstane-3β,17β-diol | 0.874 | 2.10 | * | -0.136 | -3.15 | -0.301 | ** | -0.039 | -1.84 | ||
| Cortisone | 1.256 | 3.77 | ** | -0.202 | -4.02 | -0.456 | ** | -0.056 | -2.65 | * | |
| Maternal age | 0.965 | 3.43 | ** | 0.153 | 5.17 | 0.344 | ** | 0.043 | 3.14 | ** | |
| Pregnancy length | 1.142 | 3.74 | ** | -0.077 | -1.15 | -0.172 | -0.051 | -3.04 | ** | ||
| ΔAndrostenediol sulfate | 1.477 | 18.03 | ** | -0.133 | -6.36 | -0.298 | ** | -0.065 | -7.19 | ** | |
| ΔPregnancy length | 0.982 | 3.15 | ** | 0.081 | 2.37 | 0.182 | * | 0.043 | 2.69 | * | |
| ΔDS-R, Contamination disgust | 1.000 | 11.03 | 0.545 | ** | |||||||
| Explained variability | 29.7% (24.9% after cross-validation) | ||||||||||
| ΔDS-R, Animal reminder disgust | |||||||||||
| 7-oxo-DHEA | 0.837 | 2.81 | * | -0.165 | -4.43 | -0.423 | ** | -0.029 | -3.41 | ** | |
| 20α-Dihydroprogesterone | 1.210 | 3.93 | ** | -0.238 | -4.74 | -0.608 | ** | -0.042 | -4.37 | ** | |
| 16α-Hydroxyprogesterone | 1.150 | 5.03 | ** | -0.248 | -6.41 | -0.634 | ** | -0.040 | -5.40 | ** | |
| 17α,20α-Dihydroxy-4-pregnene-3-one | 0.851 | 2.17 | * | -0.239 | -6.31 | -0.612 | ** | -0.030 | -2.95 | * | |
| Testosterone | 0.990 | 3.34 | ** | -0.271 | -13.71 | -0.692 | ** | -0.035 | -3.99 | ** | |
| 5α-Dihydrotestosterone | 0.979 | 4.33 | ** | -0.258 | -5.93 | -0.660 | ** | -0.034 | -3.38 | ** | |
| Estradiol | 0.844 | 2.62 | * | -0.164 | -3.95 | -0.414 | ** | -0.030 | -2.50 | * | |
| 17α-Hydroxyallopregnanolone | 0.898 | 4.74 | ** | -0.263 | -11.02 | -0.674 | ** | -0.031 | -3.03 | ** | |
| 17α-Hydroxypregnanolone | 0.981 | 3.14 | ** | -0.210 | -5.96 | -0.539 | ** | -0.034 | -2.82 | * | |
| 3α,5α-Tetrahydroprogsterone | 1.042 | 2.61 | * | -0.250 | -8.76 | -0.639 | ** | -0.036 | -2.59 | * | |
| 5α-Pregnane-3α,20α-diol | 0.840 | 2.34 | * | -0.248 | -5.20 | -0.635 | ** | -0.029 | -2.52 | * | |
| 3α,5β-Tetrahydroprogsterone | 1.446 | 3.89 | ** | -0.204 | -7.26 | -0.521 | ** | -0.051 | -2.67 | * | |
| 5β-Pregnane-3α,20α-diol | 1.146 | 3.78 | ** | -0.204 | -12.24 | -0.521 | ** | -0.040 | -2.69 | * | |
| 5β-Pregnane-3α,17α,20α-triol | 0.774 | 4.00 | ** | -0.212 | -8.23 | -0.545 | ** | -0.027 | -3.78 | ** | |
| Androsterone | 0.972 | 11.39 | ** | -0.273 | -7.07 | -0.699 | ** | -0.034 | -6.20 | ** | |
| Epiandrosterone | 1.023 | 3.51 | ** | -0.215 | -4.07 | -0.550 | ** | -0.036 | -2.94 | * | |
| 5α-Androstane-3α,17β-diol | 1.231 | 3.52 | ** | -0.262 | -6.79 | -0.670 | ** | -0.043 | -2.91 | * | |
| 5α-Androstane-3β,17β-diol | 1.148 | 1.93 | * | -0.217 | -3.69 | -0.554 | ** | -0.040 | -1.79 | ||
| Parity | 0.908 | 3.68 | ** | 0.081 | 1.60 | 0.206 | 0.032 | 2.84 | * | ||
| DS-R, Animal reminder disgust | 0.944 | 3.23 | ** | -0.080 | -2.67 | -0.205 | * | -0.033 | -2.36 | * | |
| Pregnancy length | 0.716 | 2.65 | * | 0.114 | 3.14 | 0.292 | ** | 0.025 | 3.18 | ** | |
| Δ5α-Dihydrotestosterone | 0.714 | 3.04 | ** | 0.204 | 5.83 | 0.523 | ** | 0.025 | 2.76 | * | |
| Δ5α-Androstane-3α,17β-diol | 1.013 | 3.00 | ** | 0.186 | 9.32 | 0.477 | ** | 0.035 | 2.32 | * | |
| ΔPregnancy length | 0.993 | 2.67 | * | 0.102 | 2.13 | 0.261 | * | 0.035 | 3.09 | ** | |
| ΔDS-R, Animal reminder disgust | 1.000 | 20.08 | 0.438 | ** | |||||||
| Explained variability | 19.2% (15.3% after cross-validation) | ||||||||||
| OPLS, predictive component | Multiple regression |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Variable importance | t-statistics | Component loading | t-statistics | Ra | Regression coefficient | t-statistics | ||||
| Pregnenolone | 0.642 | 2.83 | * | 0.183 | 1.98 | 0.259 | * | 0.075 | 1.98 | * | |
| TDDS_PATHOGEN | 1.001 | 4.05 | ** | -0.333 | -4.28 | -0.474 | ** | -0.118 | -4.83 | ** | |
| ΔEstrone sulfate | 1.140 | 3.91 | ** | 0.517 | 10.61 | 0.740 | ** | 0.134 | 2.92 | * | |
| ΔEstradiol sulfate | 1.061 | 3.80 | ** | 0.566 | 16.62 | 0.804 | ** | 0.125 | 2.67 | * | |
| ΔEstriol sulfate | 1.077 | 9.86 | ** | 0.553 | 14.69 | 0.804 | ** | 0.127 | 6.58 | ** | |
| ΔPathogen disgust (trimester 3 - trimester 1) | 1.000 | 2.72 | 0.375 | * | |||||||
| Explained variability | 14% (11.2% after cross-validation) | ||||||||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
